(Boursier.com) — For the first half, the turnover of MaaT Pharma was 0.5 ME and the cash position was 38.4 ME as of June 30, 2022.
The milestones reached in the clinical and production programs for this first half of 2022 are:
-Launch of a pivotal Phase 3, single-arm, open-label study evaluating MaaT013 in acute graft-versus-host disease in Europe in the first quarter of 2022
-Launch of a Phase 2a trial, promoted by AP-HP, evaluating MaaT013 in combination with immunotherapies in patients with metastatic melanoma in the second quarter of 2022
-Completion of a Phase 1b clinical trial to define the dosage of the MaaT033 product in hemato-oncology and publication of the main positive results
-Partnership with Skyepharma to build a production plant to GMP standards exclusively dedicated to microbiota drug candidates.
©2022 Boursier.com